Industry: it is recommended that reasonable reduce Chinese medicine product output rate

Source: netease finance and economics

        Our country has rich resources of medicinal herbs, Chinese herbal medicine industry has always been the traditional advantage industry of our country. 2010, the Chinese herbal medicine manufacturing assets reached 300 billion yuan, year-on-year growth of around 18%, nearly 5% growth year-on-year increase; More than 2300 enterprises, the total investment in fixed assets total nearly 50 billion yuan, year-on-year growth of around 16%. In the national implementation of the new medical reform policy investment, part is dedicated to support the development of traditional Chinese medicine industry. As people to the attention of the health care, national health emphasis on disease control and prevention before, and the concept of traditional Chinese medicine "cure not ill" has been deeply rooted in the hearts of the people. All these will provide more favorable conditions for the development of Chinese materia medica industry. But the Chinese medicine enterprises in our country, the small and medium-sized enterprises (smes) account for the vast majority, enterprise standardization, standardization degree is generally low, poor innovation ability. Especially the insufficiency of traditional Chinese medicine enterprise for r&d, repeat some Chinese medicine products, curative effect difference is not big, difficult to adapt to market demand. Chinese traditional medicine enterprise in order to meet the new "drug production quality management standard (revised in 2010) certification requirements, promote enterprises to achieve sustainable development, only by constantly technical innovation and product innovation, improve their core competitiveness.

        But at present, the production of raw materials, packaging materials, energy, power, and human resources costs continued to rise, especially in recent years, Chinese herbal medicine price rise is bigger, some Chinese herbal medicine prices have risen by as much as 10 times. Investigation indicated that the traditional Chinese medicine production enterprises comprehensive cost is 1-1.5 times that of 2000. Contrast is that compared with traditional Chinese medicine product basic didn't increase price, most of the product price also downgrade for many times, many enterprises profits plunged, at a small profit or loss of status, a serious shortage of enterprise technology innovation investment, innovation, enthusiasm by big blow. In addition, according to the current tax policy of our country, Chinese traditional medicine are identified as agricultural products, the VAT input tax calculated on the basis of the tax rate of 13%, while traditional Chinese medicine enterprises of traditional Chinese medicine product according to the calculation of output VAT tax rate of 17%. From the net balance, traditional Chinese medicine production enterprises sell a higher income tax rate of 4%. This virtually increase the burden of enterprises, let already thin margins of traditional Chinese medicine enterprise more difficult to bear, restricted the enterprise investment on r&d and innovation of science and technology.

        As a typical policy driven industries, the country's fiscal and taxation support policy for Chinese traditional medicine enterprise development play an important role. To this end, we suggest the way traditional Chinese medicine product output rate, decreased to 13% and the 17% of the tax system will ensure that traditional Chinese medicine production enterprises should have profit, arouse the enthusiasm of enterprise production, and promote national enterprise healthy development of Chinese medicine.

        This article source: netease finance and economics

Read the original: http://www.cngjzj.com/admin/Admin_Index.asp